Gonadotropins: Structural Features, Receptor Signaling, and Research and Application Frameworks

Gonadotropins are key endocrine effectors of the hypothalamic–pituitary–gonadal (HPG) axis and mainly include follicle-stimulating hormone (FSH) and luteinizing hormone (LH), as well as the placental hormone human chorionic gonadotropin (hCG), which exerts LH-like activity. All three belong to the glycoprotein hormone family. By binding their cognate receptors (FSHR and LHCGR), they drive signaling networks centered on cAMP/PKA and integrated with MAPK, PI3K/AKT, β-arrestin, and related pathways, thereby regulating gametogenesis, steroidogenesis, follicular development, ovulation and luteal function, and coordinated Sertoli–Leydig cell processes in the testis. In research and applied settings, gonadotropins are core tools for stimulation or replacement of reproductive-axis function and are also model systems for interrogating GPCR signaling kinetics, receptor desensitization, and glycosylation–function relationships. Because they exhibit pronounced glycosylation heterogeneity and are frequently dosed using bioactivity-defined units that are sensitive to dosing paradigms, experimental and application design should be standardized around hormone identity, receptor specificity, dose characterization, and evidence-chain controls.

Keywords: gonadotropins; FSH; LH; hCG; urinary gonadotropins; menotrophins; hMG; FSHR; LHCGR; glycoprotein hormone; glycosylation; cAMP/PKA; steroidogenesis; folliculogenesis; ovulation; spermatogenesis; ART; bioassay; quality control

I. Core Concepts and Classification Framework

1.1 Definitions and Core Members

(1) Pituitary-derived gonadotropins

① Follicle-stimulating hormone (FSH): primarily acts on ovarian granulosa cells and testicular Sertoli cells.

② Luteinizing hormone (LH): primarily acts on ovarian theca cells/luteal cells and testicular Leydig cells.

(2) Placenta-derived gonadotropins

① Human chorionic gonadotropin (hCG): binds LHCGR and produces LH-like effects, playing a key role in pregnancy maintenance and luteal support.

1.2 Preparation Sources and Common Types in Research Contexts

(1) Urine-derived preparations

① Urinary FSH (uFSH): FSH preparations derived from urine of postmenopausal women.

② Menotrophins (commonly hMG): preparations containing both FSH activity and LH activity (or LH-like activity).

(2) Recombinant preparations

① Recombinant FSH (rFSH): human FSH produced via cell-expression systems, typically with more controllable glycosylation profiles and higher lot-to-lot consistency; well suited as a standardized agonist or baseline comparator in in vitro signaling and functional studies.

② Recombinant LH (rLH): human LH produced via cell-expression systems, used to supplement or precisely control LH activity inputs; commonly used in follicle-stimulation studies to dissect “LH thresholds” and the contribution of theca-derived androgen substrates to granulosa aromatization and follicular maturation.

(3) Research implications of source differences

Urine-derived preparations generally exhibit broader glycoform distributions and more complex impurity profiles, whereas recombinant products tend to have more controllable glycosylation and stronger lot-to-lot consistency. Study design should explicitly define preparation type and potential LH-like background to avoid pathway mixing that biases mechanistic attribution.

II. Molecular Structure and Glycosylation Heterogeneity

2.1 Common α Subunit and Hormone-Specific β Subunits

(1) Heterodimeric framework

FSH, LH, and hCG are all heterodimeric glycoproteins composed of a common α subunit and distinct β subunits; the β subunit determines receptor specificity and contributes to functional selectivity.

(2) Key structure–function variables

Glycan number, branching, and terminal sialylation govern charge properties, in vivo clearance, receptor-binding kinetics, and signal duration, providing the principal molecular basis for differences in effect persistence at matched bioactivity units.

2.2 Charge Heterogeneity and In Vivo Behavior

(1) Sialylation and half-life

Higher sialylation increases overall negative charge and is commonly associated with slower clearance, thereby influencing duration of action.

(2) Glycoform heterogeneity and biased signaling

Distinct glycoforms can shift receptor conformational ensembles, internalization/recycling behavior, and β-arrestin engagement, producing differences in signaling bias and transcriptional outputs; these differences are particularly relevant when comparing urine-derived versus recombinant preparations.

III. Receptor Types and Signal-Transduction Mechanisms

3.1 Receptor Distribution and Cell-Type Specificity

(1) FSHR

Primarily expressed in ovarian granulosa cells and testicular Sertoli cells, mediating trophic, differentiation, and support-like signaling in folliculogenesis and spermatogenesis.

(2) LHCGR

Expressed in ovarian theca cells, luteal cells, and testicular Leydig cells, with critical roles in ovulation, luteinization, and androgen production; both LH and hCG signal through this receptor.

3.2 Canonical Axes and Integrated Networks

(1) cAMP/PKA central axis

① Receptor activation engages Gs, stimulates adenylyl cyclase, and elevates cAMP.

② cAMP activates PKA to regulate transcription factors such as CREB and drive expression of steroidogenic genes.

(2) MAPK and PI3K/AKT pathways

Gonadotropins can activate ERK/MAPK and PI3K/AKT, influencing proliferation, survival, and differentiation.

(3) β-arrestin and receptor internalization

β-arrestin contributes to desensitization, internalization, and signaling scaffolding, shaping signal persistence and biased outputs.

(4) Desensitization and resensitization

Sustained stimulation can induce desensitization and reshape transcriptional responses. Intermittent stimulation yields distinct kinetics and signaling-memory behaviors, making stimulation paradigms a key variable in both experimental and dosing strategy design.

IV. Physiological Functions: Coordinated Logic in Ovary and Testis

4.1 Ovary: The Two-Cell/Two-Gonadotropin Model

(1) LH/hCG responses in theca cells

LH/hCG stimulates theca cells to synthesize androgen precursors that serve as substrates for granulosa-cell aromatization.

(2) FSH responses in granulosa cells

FSH promotes granulosa-cell proliferation and differentiation, upregulates aromatase, and drives estrogen production, contributing to follicle selection and dominant follicle formation.

(3) Ovulation and luteinization

The LH surge triggers ovulation and induces luteinization; during pregnancy, hCG provides sustained LH-like support to maintain luteal function.

4.2 Testis: Sertoli–Leydig Cell Cooperation

(1) FSH effects on Sertoli cells

FSH enhances trophic support and paracrine regulation by Sertoli cells and influences expression of proteins associated with the blood–testis barrier.

(2) LH effects on Leydig cells

LH stimulates Leydig-cell testosterone synthesis; testosterone and Sertoli-cell signals jointly maintain the spermatogenic microenvironment.

(3) Feedback regulation

Inhibin/activin and sex steroids exert negative feedback on pituitary gonadotropin secretion to maintain reproductive-axis homeostasis.

V. Research Applications: Model Systems, Readouts, and Mechanistic Evidence Chains

5.1 Cell Models and Multi-Layer Readouts

(1) Granulosa/theca cell models

① cAMP and CREB phosphorylation, ERK dynamics.

② Steroid profiles and expression of key enzymes (STAR, CYP11A1, CYP19A1, etc.).

③ Proliferation, apoptosis, and differentiation markers.

(2) Sertoli/Leydig cell models

① Testosterone synthesis and steroidogenic gene expression.

② Paracrine factors and junctional-structure indices.

(3) Specificity validation

① Receptor-blocking antibodies or antagonists.

② Receptor knockdown/knockout.

③ Pathway inhibition controls (PKA, MEK, PI3K, etc.).

5.2 Biased Signaling and Glycosylation–Function Relationships

(1) Bias assessment framework

① Compare multi-pathway outputs such as cAMP versus β-arrestin recruitment and ERK time courses.

② Evaluate contributions of internalization and recycling to signal persistence.

③ Jointly analyze signaling readouts with functional endpoints (steroid profiles, proliferation/differentiation).

(2) Preparation-control strategies

① Run urine-derived and recombinant preparations in parallel to isolate glycoform-driven contributions.

② Use within-lot standard curves and cross-lot bridging calibration to control lot drift.

5.3 In Vitro Follicle Culture, Organoids, and Tissue-Level Models

(1) Follicle culture

① Follicle diameter growth, antrum formation, and granulosa-layer organization.

② Steroid secretion profiles and gene expression.

(2) Spatially resolved readouts

In tissue sections, spatial transcriptomics, or in situ imaging systems, gonadotropins can be used as exogenous perturbations to assess local responses in receptor-expressing regions.

VI. Menotrophins (hMG): Formulation Features and Application Considerations

6.1 Definition, Composition, and Potency Ratios

(1) Formulation definition

Menotrophins are glycoprotein hormone preparations extracted from urine of postmenopausal women, with FSH and LH as major components.

(2) Practical meaning of the FSH:LH potency ratio

① Many preparations have an FSH:LH potency ratio close to 1:1, forming the pharmacological basis for cooperative theca (LH)–granulosa (FSH) stimulation.

② Research interpretation must explicitly account for this composite activity background to avoid misattributing LH-like effects to isolated FSH action.

③ If single-receptor attribution is required, include LHCGR-pathway controls or choose low-LH-background preparations.

6.2 Dosage Form, Appearance, and Storage Management

(1) Dosage form and typical strengths

① Commonly supplied as lyophilized powder for injection, often labeled as 75 IU and 150 IU (typically in FSH potency equivalents).

② Administration is mainly intramuscular or subcutaneous; oral absorption is negligible.

(2) Appearance and solubility

① Typically off-white to pale yellow powder.

② Water-soluble; reconstitution requires aseptic handling and use-window management.

(3) Storage conditions

Protect from light, keep sealed, and store cold; post-reconstitution conditions and time limits should follow product-specific instructions.

6.3 Pharmacopoeial QC Logic and Key Comparability Points

(1) Source and viral safety control

① Raw materials should be sourced from healthy donor populations.

② Manufacturing should incorporate appropriate viral inactivation/removal risk-control steps.

(2) Potency and bioassays

① Both FSH and LH potencies are determined by bioassays and are required to fall within a specified range of the labeled claim (commonly 80%–125%).

② IU is a bioactivity reference and is not equivalent to mass or molar concentration; cross-lot comparisons benefit from supplemental immunoquantitation and charge/glycoform characterization.

(3) Impurity and safety-related metrics

① Endotoxin limits are often defined per unit activity to constrain non-specific immune activation risk.

② Physicochemical tests (e.g., loss on drying, residual solvents) constrain stability and process consistency.

(4) Biological consistency verification

Traditional identification may use animal target-organ weight gain as a proxy for gonadotropin activity consistency; in research and QC, receptor-specific cell-based assays and downstream signaling readouts can serve as alternatives or complements.

VII. Application Frameworks: Testing, Diagnosis, and Assisted Reproduction Contexts

7.1 Bioassays and Standardization

(1) Activity units and comparability

Gonadotropin preparations are commonly defined in IU, a bioactivity reference. For research and QC, reporting IU together with immunoquantified concentrations, and building standard curves and bridging calibrations, improves comparability.

(2) Common assays and characterization

① Immunoassays for concentration quantification.

② Charge-heterogeneity analyses for lot consistency and prediction of in vivo behavior.

③ Endotoxin, aggregates, and residual impurities to constrain safety and readout reliability.

7.2 Female Applications: Follicle Stimulation, Ovulation Triggering, and Luteal Support

(1) Cooperative follicle stimulation and maturation

① FSH promotes granulosa-cell proliferation and development of aromatization capacity.

② LH acts on theca cells to provide androgen substrates and participates in maturation programs; together they drive rising estrogen and endometrial proliferation.

(2) Ovulation triggering and luteal support

In stimulation cycles, hCG is often used after follicle maturation to trigger ovulation-related events and support luteal-phase strategies.

(3) Individualized variables

Ovarian responsiveness, clearance differences, and receptor sensitivity shape intensity and duration of stimulation; kinetic monitoring and multi-endpoint evaluation are used to constrain excessive-stimulation risk.

7.3 Male Applications: Support of Spermatogenesis and Hypogonadism

(1) Cooperative logic

① FSH acts on Sertoli cells to maintain the spermatogenic microenvironment.

② LH-like activity stimulates Leydig-cell testosterone production, which cooperates with Sertoli signaling to support spermatogenesis.

(2) Evidence-chain endpoints

Semen parameters, testosterone levels, and inhibin B can form a multi-layer evidence chain to assess response and efficacy trends.

VIII. Safety and Monitoring: A Risk-Control Framework Centered on OHSS

8.1 Ovarian Hyperstimulation Syndrome (OHSS) and Multiple-Gestation Risk

(1) Risk origin

Gonadotropin stimulation may drive multi-follicular development, increasing OHSS and multiple-gestation risk; trigger strategy and individual ovarian responsiveness jointly determine risk levels.

(2) Monitoring and dose-adjustment essentials

① Ultrasound monitoring of follicle count, diameter distribution, and ovarian volume.

② Combined hormone measurements (e.g., estradiol) to estimate response intensity.

③ Use monitoring results to guide dose escalation, reduction, or withholding to avoid high-risk zones.

8.2 Allergy and Thromboembolism Risk Notes

(1) Allergic reactions

Urine-derived protein preparations may pose allergy risk; prior allergy history and injection-site/systemic reactions should be monitored.

(2) Thromboembolic risk

High-estrogen states and OHSS may increase thrombotic risk; high-risk populations require strengthened risk assessment and monitoring.

IX. Methodological Considerations and Common Pitfalls

9.1 Key Confounders

① Differences in LH-like activity among preparations can introduce pathway mixing.

② Glycoform heterogeneity can yield different kinetics at matched IU.

③ Endotoxin and aggregates can trigger non-specific stress responses.

④ Receptor expression varies with cellular maturity, reducing cross-group comparability.

9.2 Standardization Recommendations

① Specify hormone identity, source, and purity, and report these in Methods.

② Establish within-lot standard curves and cross-lot bridging calibration to prevent misattributing lot differences to treatment effects.

③ Use receptor-specific controls and pathway-inhibition controls to build mechanistic evidence chains.

④ Report signaling, transcriptional, and functional endpoints in parallel to avoid overextending single-readout conclusions.

X. Aladdin-Related Products

10.1 Urine-Derived Gonadotropin Preparations (Gonadotropins/uHMG)

Catalog No.	Product Name	Grade and Purity
G110311	Gonadotropin from human menopausal urine	>200 I.U. per mg
C1510520	Menotrophin (HMG)
C1510521	Menotrophin (HMG)

10.2 Key Reagents for Gonadotropin Research Workflows (Two-Cell Models, Dissecting LH-Like Activity, Receptor Kinetics, and Steroidogenesis)

Name	CAS No.	Use Stage	Role in the Workflow	Handling Notes
Aminoglutethimide	125-84-8	Steroidogenesis pathway localization	Inhibits CYP11A1-associated steps to test whether “cholesterol → pregnenolone” is rate-limiting	Use short windows and dose gradients; include vehicle controls to avoid misinterpretation from broad suppression
Trilostane	13647-35-3	Steroid-profile branch validation	Inhibits 3β-HSD to block the pregnenolone → progesterone/androstenedione branch	Well suited for steroid-panel readouts to observe “precursor accumulation/downstream decrease”
Abiraterone	154229-19-3	Theca-cell androgen supply validation	Inhibits CYP17A1 to test dependence of FSH-driven aromatization on LH-side androgen substrate supply	Watch solubility and cytotoxicity; interpret jointly with androgen/estrogen profiling
Letrozole	112809-51-5	Granulosa aromatization validation	Inhibits CYP19A1 to test whether FSH-induced E2 arises from aromatization	E2 decrease plus androgen-precursor increase is more interpretable; include vehicle controls
Pregnenolone	145-13-1	Pathway localization/supplementation	Upstream precursor supplementation to test whether the CYP11A1 step is a bottleneck	Combine with aminoglutethimide for “block-and-rescue” validation; include vehicle controls
Progesterone	57-83-0	Functional endpoint/standard	Standard curve, spike-and-recovery, and matrix-effect assessment for P4 readouts	Fix solvent fraction; use matrix-matched calibration or standard addition to improve recovery accuracy
Estradiol (17β-estradiol, E2)	50-28-2	Functional endpoint/standard	Granulosa aromatization endpoint standard for E2 quantification and recovery checks	Control plastic adsorption and dissolution method; fix carrier system and perform spike-and-recovery
22(R)-Hydroxycholesterol	20380-11-4	Substrate accessibility validation	Bypasses some cholesterol-transport limitations to probe the upper bound of steroidogenesis as a “substrate accessibility/delivery” variable	Compare with cholesterol to distinguish “delivery limitation” from “enzymatic limitation”; standardize solvent/carrier systems
Carbenoxolone	7421-40-1	Hormone-background/metabolic-interference control (as needed)	Used in some systems to manage steroid-metabolism-related background (model-dependent)	Use only when background interference is demonstrated; define necessity and toxicity windows in pilot tests
BSA (bovine serum albumin)	9048-46-8	Carrier and hydrophobic-substrate delivery	Stabilizes hydrophobic substrates (cholesterol/steroids) and reduces adsorption to improve stimulation consistency	Matched carrier controls are required; fix lot and low-endotoxin grade to avoid inflammation-background drift

FSH, LH, and hCG are core gonadotropins that regulate ovarian and testicular function through GPCR signaling networks mediated by FSHR and LHCGR, serving as foundational effectors in reproductive endocrinology research and application. Menotrophins (hMG) are a representative urine-derived composite preparation combining FSH and LH activities and enabling cooperative stimulation; its QC framework emphasizes source control, viral safety, potency bioassays, and endotoxin limits as key quality attributes. By explicitly defining preparation types and composite-activity backgrounds, implementing rigorous dose characterization and inter-lot comparability controls, applying receptor-specific controls and multi-layer evidence-chain readouts, and managing risk using ultrasound and hormone monitoring, researchers and practitioners can achieve interpretable, reproducible scientific conclusions and application outputs.

For more related articles, please see below:

[1] Latex coagulation system inhibition assay for human chorionic gonadotropin assay

[2] Enzyme immunoassay for human chorionic gonadotropin assay